The success of the Walkman back in the 1980s is testament to the power of getting to market first. By some accounts, Sony sold over 200 million units of its innovative portable cassette player (http://nnw.fm/H6spU). Now, India Globalization Capital, Inc. (NYSE MKT: IGC) is taking a leaf from the Sony playbook. This pioneering company is a ‘first mover’ in the cannabinoid combination therapy space. IGC is developing a portfolio of products that use cannabinoids in conjunction with existing drugs to tackle chronic pain and a variety of other debilitating medical conditions.
Chronic pain from a range of ailments plagues millions around the world, and many of the analgesics employed to treat it, such as morphine, codeine, and hydrocodone, are opioids. However, opioids are notoriously addictive and their use is often subverted from pain relief. Used as recreational drugs, ‘opioid addiction is America’s 50-state epidemic’, the New York Times has reported (http://nnw.fm/8UBpU), with an effect that is fatal in many instances. According to the Centers for Disease Control (CDC), 29,000 Americans die every year from opioid-related overdoses. In light of these frightening developments, there is a growing imperative for less addictive anodynes.
Read the full article
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
India Globalization Capital, Inc. (NYSE: IGC) is a First Mover in Cannabinoid Combination Therapies
